Rossi Luigia, Pierigè Francesca, Agostini Marco, Bigini Noemi, Termopoli Veronica, Cai Yingting, Zheng Fang, Zhan Chang-Guo, Landry Donald W, Magnani Mauro
Department of Biomolecular Sciences, University of Urbino, Urbino, Italy.
EryDel S.p.A., Milan, Italy.
Front Physiol. 2020 Sep 10;11:573492. doi: 10.3389/fphys.2020.573492. eCollection 2020.
Recombinant bacterial cocaine esterase (CocE) represents a potential protein therapeutic for cocaine use disorder treatment. Unfortunately, the native enzyme was highly unstable and the corresponding mutagenized derivatives, RBP-8000 and E196-301, although improving thermo-stability and half-life, were a partial solution to the problem. For cocaine use disorder treatment, an efficient cocaine-metabolizing enzyme with a longer residence time in circulation would be needed. We investigated the possibility of developing red blood cells (RBCs) loaded with RBP-8000 and E196-301 as a biocompatible system to metabolize cocaine for a longer period of time. RBP 8000 stability within human RBCs is limited (approximately 50% residual activity after 1 h at 37°C) and not different as for the free enzyme, while both free and encapsulated E196-301 showed a greater thermo-stability. By reducing cellular glutathione content during the loading procedure, in order to preserve the disulfide bonds opportunely created to stabilize the enzyme dimer structure, it was possible to produce an encapsulated protein maintaining 100% stability at least after 4 h at 37°C. Moreover, E196-301-loaded RBCs were efficiently able to degrade cocaine in a time- and concentration-dependent manner. The same stability results were obtained when murine RBCs were used paving the way to preclinical investigations. Thus, our data show that E196-301-loaded RBCs could act as efficient bioreactors in degrading cocaine to non-toxic metabolites to be possibly considered in substance-use disorder treatments. This approach should now be investigated in a preclinical model of cocaine use disorder to evaluate if further protein modifications are needed to further improve long term enzyme stability.
重组细菌可卡因酯酶(CocE)是治疗可卡因使用障碍的一种潜在蛋白质疗法。不幸的是,天然酶高度不稳定,相应的诱变衍生物RBP - 8000和E196 - 301虽然提高了热稳定性和半衰期,但只是部分解决了问题。对于可卡因使用障碍的治疗,需要一种在循环中停留时间更长的高效可卡因代谢酶。我们研究了开发负载RBP - 8000和E196 - 301的红细胞(RBC)作为生物相容性系统以更长时间代谢可卡因的可能性。RBP 8000在人红细胞内的稳定性有限(37°C下1小时后约50%的残余活性),与游离酶无差异,而游离和包封的E196 - 301都表现出更高的热稳定性。在加载过程中通过降低细胞内谷胱甘肽含量,以保留为稳定酶二聚体结构而适当形成的二硫键,有可能产生一种包封蛋白,至少在37°C下4小时后仍保持100%的稳定性。此外,负载E196 - 301的红细胞能够以时间和浓度依赖的方式有效降解可卡因。使用小鼠红细胞时也获得了相同的稳定性结果,为临床前研究铺平了道路。因此,我们的数据表明,负载E196 - 301的红细胞可以作为高效生物反应器,将可卡因降解为无毒代谢物,这可能在物质使用障碍治疗中得到考虑。现在应该在可卡因使用障碍的临床前模型中研究这种方法,以评估是否需要进一步的蛋白质修饰来进一步提高酶的长期稳定性。